Adam P. Curnock

785 total citations
17 papers, 583 citations indexed

About

Adam P. Curnock is a scholar working on Molecular Biology, Oncology and Immunology. According to data from OpenAlex, Adam P. Curnock has authored 17 papers receiving a total of 583 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Molecular Biology, 10 papers in Oncology and 5 papers in Immunology. Recurrent topics in Adam P. Curnock's work include Cytokine Signaling Pathways and Interactions (6 papers), Chemokine receptors and signaling (4 papers) and Biochemical and Molecular Research (3 papers). Adam P. Curnock is often cited by papers focused on Cytokine Signaling Pathways and Interactions (6 papers), Chemokine receptors and signaling (4 papers) and Biochemical and Molecular Research (3 papers). Adam P. Curnock collaborates with scholars based in United Kingdom, United States and France. Adam P. Curnock's co-authors include Stephen G. Ward, Christopher Yea, Robert Westwood, Suresh Jivan Gadher, E. Ruuth, P.A. Robson, Yannis Sotsios, Karen L. Wright, Richard A. Williamson and Tom Thomson and has published in prestigious journals such as Journal of Biological Chemistry, The Journal of Immunology and Diabetes.

In The Last Decade

Adam P. Curnock

16 papers receiving 564 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Adam P. Curnock United Kingdom 11 286 172 169 60 48 17 583
Troii Hall United States 14 625 2.2× 182 1.1× 207 1.2× 44 0.7× 47 1.0× 24 943
Katherine A. Rouleau United States 13 221 0.8× 152 0.9× 176 1.0× 126 2.1× 88 1.8× 17 548
Stéphane Olland United States 11 524 1.8× 169 1.0× 175 1.0× 85 1.4× 19 0.4× 16 761
Matthew J. Saabye United States 8 267 0.9× 159 0.9× 190 1.1× 69 1.1× 41 0.9× 8 703
John F. MacMaster United States 11 411 1.4× 378 2.2× 296 1.8× 137 2.3× 50 1.0× 13 993
Amy E. Adams United States 10 479 1.7× 115 0.7× 261 1.5× 22 0.4× 34 0.7× 14 724
Gregg Timony United States 11 545 1.9× 142 0.8× 73 0.4× 107 1.8× 59 1.2× 24 882
Alok R. Singh United States 16 494 1.7× 197 1.1× 216 1.3× 75 1.3× 41 0.9× 25 858
Sarah C. Nabinger United States 13 434 1.5× 196 1.1× 138 0.8× 30 0.5× 37 0.8× 23 637
Marianne Scheel Fjording Denmark 11 303 1.1× 238 1.4× 125 0.7× 49 0.8× 16 0.3× 17 610

Countries citing papers authored by Adam P. Curnock

Since Specialization
Citations

This map shows the geographic impact of Adam P. Curnock's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Adam P. Curnock with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Adam P. Curnock more than expected).

Fields of papers citing papers by Adam P. Curnock

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Adam P. Curnock. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Adam P. Curnock. The network helps show where Adam P. Curnock may publish in the future.

Co-authorship network of co-authors of Adam P. Curnock

This figure shows the co-authorship network connecting the top 25 collaborators of Adam P. Curnock. A scholar is included among the top collaborators of Adam P. Curnock based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Adam P. Curnock. Adam P. Curnock is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Depoil, David, et al.. (2021). 1016P ImmTAC redirect exhausted tumor-infiltrating T-cells: An effect enhanced by pembrolizumab against PD-L1+ tumors. Annals of Oncology. 32. S856–S856. 2 indexed citations
2.
Bossi, Giovanna, Adam P. Curnock, Peter Weber, et al.. (2021). 58-LB: ß-Cell Targeted Immune Suppressive PD-1 Bispecific Agonists: A Novel Approach to Treat Type 1 Diabetes. Diabetes. 70(Supplement_1).
3.
Collier, Philip N., Heather Twin, Ronald M. A. Knegtel, et al.. (2019). Discovery of Selective, Orally Bioavailable Pyrazolopyridine Inhibitors of Protein Kinase Cθ (PKCθ) That Ameliorate Symptoms of Experimental Autoimmune Encephalomyelitis. ACS Medicinal Chemistry Letters. 10(8). 1134–1139. 9 indexed citations
4.
Rué, Laura, Bart Roucourt, Mieke Timmers, et al.. (2017). Identification and characterization of Nanobodies targeting the EphA4 receptor. Journal of Biological Chemistry. 292(27). 11452–11465. 25 indexed citations
5.
Curnock, Adam P., Pky Chiu, Matthias Hesse, et al.. (2014). Selective protein kinase Cθ (PKCθ) inhibitors for the treatment of autoimmune diseases. Biochemical Society Transactions. 42(6). 1524–1528. 10 indexed citations
6.
Jimenez, Juan‐Miguel, Dean Boyall, Philip N. Collier, et al.. (2013). Design and Optimization of Selective Protein Kinase C θ (PKCθ) Inhibitors for the Treatment of Autoimmune Diseases. Journal of Medicinal Chemistry. 56(5). 1799–1810. 34 indexed citations
7.
Jimenez, Juan‐Miguel, Christopher J. Davis, Dean Boyall, et al.. (2012). Structure-based optimization of aminopyridines as PKCθ inhibitors. Bioorganic & Medicinal Chemistry Letters. 22(14). 4645–4649. 10 indexed citations
8.
Charrier, Jean‐Damien, Andrew T. Miller, David P. Kay, et al.. (2011). Discovery and Structure−Activity Relationship of 3-Aminopyrid-2-ones as Potent and Selective Interleukin-2 Inducible T-Cell Kinase (Itk) Inhibitors. Journal of Medicinal Chemistry. 54(7). 2341–2350. 46 indexed citations
9.
Curnock, Adam P., Yannis Sotsios, Karen L. Wright, & Stephen G. Ward. (2003). Optimal Chemotactic Responses of Leukemic T Cells to Stromal Cell-Derived Factor-1 Requires the Activation of Both Class IA and IB Phosphoinositide 3-Kinases. The Journal of Immunology. 170(8). 4021–4030. 51 indexed citations
10.
Curnock, Adam P., Yannis Sotsios, & Stephen G. Ward. (2003). Assessing the Role of Multiple Phosphoinositide 3-Kinases in Chemokine Signaling: Use of Dominant Negative Mutants Controlled by a Tetracycline-Regulated Gene Expression System. Humana Press eBooks. 239. 211–222. 2 indexed citations
11.
Curnock, Adam P. & Stephen G. Ward. (2003). Development and characterisation of tetracycline-regulated phosphoinositide 3-kinase mutants: assessing the role of multiple phosphoinositide 3-kinases in chemokine signaling. Journal of Immunological Methods. 273(1-2). 29–41. 20 indexed citations
12.
Curnock, Adam P., et al.. (2002). Chemokine signalling: pivoting around multiple phosphoinositide 3‐kinases. Immunology. 105(2). 125–136. 120 indexed citations
13.
14.
15.
Curnock, Adam P., P.A. Robson, Christopher Yea, et al.. (1997). Potencies of Leflunomide and HR325 as Inhibitors of Prostaglandin Endoperoxide H Synthase-1 and -2: Comparison with Nonsteroidal Anti-Inflammatory Drugs. Journal of Pharmacology and Experimental Therapeutics. 282(1). 339–347. 14 indexed citations
16.
Williamson, R., Christopher Yea, P.A. Robson, et al.. (1996). Dihydroorotate dehydrogenase is a target for the biological effects of leflunomide.. PubMed. 28(6). 3088–91. 37 indexed citations
17.
Williamson, Richard A., Christopher Yea, P.A. Robson, et al.. (1995). Dihydroorotate Dehydrogenase Is a High Affinity Binding Protein for A77 1726 and Mediator of a Range of Biological Effects of the Immunomodulatory Compound. Journal of Biological Chemistry. 270(38). 22467–22472. 173 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Troii Hall Breakdown of academic impact, for papers by Katherine A. Rouleau Breakdown of academic impact, for papers by Stéphane Olland Breakdown of academic impact, for papers by Matthew J. Saabye Breakdown of academic impact, for papers by John F. MacMaster Breakdown of academic impact, for papers by Amy E. Adams Breakdown of academic impact, for papers by Gregg Timony Breakdown of academic impact, for papers by Alok R. Singh Breakdown of academic impact, for papers by Sarah C. Nabinger Breakdown of academic impact, for papers by Marianne Scheel Fjording
Rankless by CCL
2026